Protalix FY2022 net loss narrows to $14.9M; CHMP positive opinion for PRX-102; FDA PDUFA May 9

Protalix BioTherapeutics, Inc.

2022-FY EPS reported -$0.31 revenue$47,638,000

Net loss of $14.9M ($0.31/share) vs $27.6M ($0.62/share) in FY2021; revenue from goods up 51% to $25.3M.
EMA CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for Fabry disease; EC decision expected May 2023.
FDA accepted resubmitted BLA for PRX-102 with PDUFA action date of May 9, 2023; milestone payment from Chiesi if approved.
Cash and equivalents $22.2M at Dec 31, 2022; voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Protalix BioTherapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $25.3 million.

Period: the fiscal year ended December 31, 2022
Revenue: $25.3 million
Result: reported results

Exact text from the filing

Committee. Financial Results For the year ended December 31, 2022, compared to the year ended December 31, 2021 ● The Company recorded revenues from selling goods of $25.3 million for the year ended December 31, 2022, an increase of $8.6 million, or 51%, compared to revenues of $16.7 million for the year ended December 31, 2021. The increase resulted from

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-002100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.